<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00232583</url>
  </required_header>
  <id_info>
    <org_study_id>1003-623</org_study_id>
    <nct_id>NCT00232583</nct_id>
  </id_info>
  <brief_title>Preservation of Beta-cell Function in Type 2 Diabetes Mellitus</brief_title>
  <official_title>Preservation of Beta-cell Function in Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Texas Southwestern Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study evaluates the rate beta-cell function decline in newly diagnosed type 2 diabetic
      patients on two different treatment regimens: insulin and metformin versus glyburide,
      metformin and pioglitazone.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a 72 months long randomized clinical trial longitudinally evaluating beta-cell
      function, as well as glycemic control and inflammatory markers in newly diagnosed type 2
      diabetic patients on two different treatment regimens: insulin and metformin versus
      glyburide, metformin and pioglitazone.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2003</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Beta-cell Function - C-peptide AUC (Area Under the Curve)</measure>
    <time_frame>72 months</time_frame>
    <description>C-peptide AUC during a 3-hours mixed meal challenge testing</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Insulin Sensitivity as Measure be Matsuda Index</measure>
    <time_frame>72 months</time_frame>
    <description>C-peptide-based Matsuda index using following formula: Matsuda index = 500,00 / root square [(fasting c-peptide x fasting glucose x 333) x (average c-peptide 0-120 mins x average glucose 0-120 mins x 333). Higher the Matsuda index, better the insulin sensitivity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bet-cell Function Measured by Disposition Index</measure>
    <time_frame>72 months</time_frame>
    <description>Disposition index was measured by multiplying the insulin secretion (C-peptide AUC/C-peptide AUC glucose) by the Matsuda index. Disposition index reflects the beta-cell function adjusted for total body insulin sensitivity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight</measure>
    <time_frame>72 months</time_frame>
    <description>Body Weight</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory Markers - hsCRP</measure>
    <time_frame>72 months</time_frame>
    <description>Inflammatory markers - hsCRP (C reactive protein)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory Markers -Fibrinogen</measure>
    <time_frame>72 months</time_frame>
    <description>Inflammatory markers - Fibrinogen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory Markers - PAI-1</measure>
    <time_frame>72 months</time_frame>
    <description>Inflammatory markers - PAI-1 (Plasminogen activator inhibitor type 1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Survey (QoL) - Current Health Perception</measure>
    <time_frame>72 months</time_frame>
    <description>Current health perception was measured at randomization and 72 months later using the modified Diabetes Quality of Life Clinical Trial Questionnaire. This questionnaire addresses several areas with respect to diabetes QoL. Answers are in the form of a Likert scale score of 1-5, where 1 = much better than 3 months ago; 2 - Somewhat better now than 3 months ago; 3 - About the same; 4 - Somewhat worse now than 3 months ago; 5 Much worse now than 3 months ago.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Survey (QoL) - Treatment Satisfaction</measure>
    <time_frame>72 months</time_frame>
    <description>Treatment satisfaction was measured at randomization and 72 months later using the modified Diabetes Quality of Life Clinical Trial Questionnaire. This questionnaire addresses several areas with respect to diabetes QoL. Answers are in the form of a Likert scale score of 1-5, where 1 - very satisfied; 2 - moderately satisfied; 3 - neither satisfied nor dissatisfied; 4 - moderately dissatisfied; 5 - very dissatisfied.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Survey (QoL) - Treatment Impact</measure>
    <time_frame>72 months</time_frame>
    <description>Treatment impact was measured at randomization and 72 months later using the modified Diabetes Quality of Life Clinical Trial Questionnaire. This questionnaire addresses several areas with respect to diabetes QoL. Answers are in the form of a Likert scale score of 1-5, where 1 - very satisfied; 2 - moderately satisfied; 3 - neither satisfied nor dissatisfied; 4 - moderately dissatisfied; 5 - very dissatisfied.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Survey (QoL) - Social or Vocational Worry</measure>
    <time_frame>72 months</time_frame>
    <description>Social or vocational worry was measured at randomization and 72 months later using the modified Diabetes Quality of Life Clinical Trial Questionnaire. This questionnaire addresses several areas with respect to diabetes QoL. Answers are in the form of a Likert scale score of 0-5, where 0 - does not apply; 1 - never; 2 - seldom; 3 - sometimes; 4 - often; 5 - all of the time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Survey (QoL) - Hypoglycemia Fear</measure>
    <time_frame>72 months</time_frame>
    <description>Hypoglycemia fear was measured at randomization and 72 months later using the modified Diabetes Quality of Life Clinical Trial Questionnaire. This questionnaire addresses several areas with respect to diabetes QoL. Answers are in the form of a Likert scale score of 1-5, where 1 - never worry; 2 - rarely water; 3 - sometimes worry; 4 - often worry; 5 - very often worry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Survey (QoL) - Glycemia Control Perception</measure>
    <time_frame>72 months</time_frame>
    <description>Glycemia control perception was measured at randomization and 72 months later using the modified Diabetes Quality of Life Clinical Trial Questionnaire. This questionnaire addresses several areas with respect to diabetes QoL. Answers are in the form of a scale score of 1-7, where 1 - extremely controlled and 7 - not at all controlled.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Survey (QoL) - Lifestyle Flexibility</measure>
    <time_frame>72 months</time_frame>
    <description>Lifestyle flexibility was measured at randomization and 72 months later using the modified Diabetes Quality of Life Clinical Trial Questionnaire. This questionnaire addresses several areas with respect to diabetes QoL. Answers are in the form of a Likert scale score of 1 to 5, where 1 - a great deal of choice; 2 - a lot of choice; 3 - some choice; 4 - a little choice; 5 - no choice.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Survey (QoL) - Social Stigma</measure>
    <time_frame>72 months</time_frame>
    <description>Social stigma was measured at randomization and 72 months later using the modified Diabetes Quality of Life Clinical Trial Questionnaire. This questionnaire addresses several areas with respect to diabetes QoL. Answers are in the form of a Likert scale score of 1 to 5, where 1- strongly agree; 2 - somewhat agree; 3 - neither agree nor disagree; 4 - somewhat disagree; 5 - strongly disagree.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Survey (QoL) - Satisfaction With Insulin Treatment</measure>
    <time_frame>72 months</time_frame>
    <description>Satisfaction with insulin treatment was measured at randomization and 72 months later using the modified Diabetes Quality of Life Clinical Trial Questionnaire. This questionnaire addresses several areas with respect to diabetes QoL. Answers are in the form of a scale score of 1 to 7, where 1 extremely satisfied to 7 - not at all satisfied.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Survey (QoL) - Willingness to Continue Insulin Treatment</measure>
    <time_frame>72 months</time_frame>
    <description>Willingness to continue insulin treatment was measured at randomization and 72 months later using the modified Diabetes Quality of Life Clinical Trial Questionnaire. This questionnaire addresses several areas with respect to diabetes QoL. Answers are in the form of a scale score of 1 to 7, where 1 extremely willing to 7 - not at all willing.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">58</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Metfomin and Insulin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Metformin 1000mg/BID and Insulin Novolog 70/30 per protocol titration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metformin, Pioglitazone and Glyburide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Metformin 1000mg/BID, Pioglitazone 45 mg and glyburide per protocol titration</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Metformin 1000mg/BID</description>
    <arm_group_label>Metfomin and Insulin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin</intervention_name>
    <description>Insulin Novolg 70/30 per protocol titration</description>
    <arm_group_label>Metfomin and Insulin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metfomin</intervention_name>
    <description>Metformin 1000mg/BID</description>
    <arm_group_label>Metformin, Pioglitazone and Glyburide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pioglitazone</intervention_name>
    <description>Pioglitazone 45mg</description>
    <arm_group_label>Metformin, Pioglitazone and Glyburide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>glyburide</intervention_name>
    <description>Glyburide per protocol titration</description>
    <arm_group_label>Metformin, Pioglitazone and Glyburide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  type 2 diabetes mellitus diagnosed within the prior 2 months

          -  HbA1c &gt; 7% at the time of inclusion

          -  willing to perform intensive diabetes management

          -  able to comply with treatment and follow-up regimen

        Exclusion Criteria:

          -  HbA1c &gt; 8% at time of randomization

          -  creatinine &gt; 1.5 mg/dl

          -  liver function tests &gt; 3 times the upper limit of normal

          -  severe anemia

          -  severe proliferative retinopathy

          -  NYHA class III or IV heart failure

          -  active CAD or recent (within 6 months) MI

          -  pregnant, willing to get pregnant, or not willing to practice any contraceptive method

          -  non-english speaking

          -  active heavy alcohol or illicit drug users (within past 6 months)

          -  history of lactic acidosis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philip Raskin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ildiko Lingvay, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas Southwestern</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Lingvay I, Kaloyanova PF, Adams-Huet B, Salinas K, Raskin P. Insulin as initial therapy in type 2 diabetes: effective, safe, and well accepted. J Investig Med. 2007 Mar;55(2):62-8. doi: 10.2310/6650.2007.06036.</citation>
    <PMID>17362692</PMID>
  </results_reference>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 30, 2005</study_first_submitted>
  <study_first_submitted_qc>September 30, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 4, 2005</study_first_posted>
  <results_first_submitted>October 15, 2013</results_first_submitted>
  <results_first_submitted_qc>May 26, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 28, 2015</results_first_posted>
  <last_update_submitted>November 17, 2017</last_update_submitted>
  <last_update_submitted_qc>November 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Texas Southwestern Medical Center</investigator_affiliation>
    <investigator_full_name>Ildiko Lingvay</investigator_full_name>
    <investigator_title>MD, MPH, MSCS</investigator_title>
  </responsible_party>
  <keyword>TYpe 2 diabetes mellitus</keyword>
  <keyword>Newly diagnosed</keyword>
  <keyword>Beta-cell function</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Pioglitazone</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Glyburide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients recruited at UT Southwestern Clinical Diabetes Research Office</recruitment_details>
      <pre_assignment_details>A 3-months run-in period preceeded randomization. During this period all patients were treated with insulin and metformin.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Metfomin &amp; Insulin</title>
          <description>Insulin NovoLog 70/30 BID adjusted to target fasting blood glucose level of 70 to 110 mg/dL and postprandial blood sugar &lt; 140 mg/dL and Metformin 2,000 mg/day (or maximum tolerated dose).</description>
        </group>
        <group group_id="P2">
          <title>Metfomin, Pioglitazone &amp; Glyburide</title>
          <description>Metformin 2,000 mg (or maximum tolerated dose); glyburide 1.25 mg BID and 15 mg daily pioglitazone (pioglitazone was titrated monthly to a final dose of 45 mg daily).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Metfomin &amp; Insulin</title>
          <description>Insulin NovoLog 70/30 BID adjusted to target fasting blood glucose level of 70 to 110 mg/dL and postprandial blood sugar &lt; 140 mg/dL and Metformin 2,000 mg/day (or maximum tolerated dose).</description>
        </group>
        <group group_id="B2">
          <title>Metfomin, Pioglitazone &amp; Glyburide</title>
          <description>Metformin 2,000 mg (or maximum tolerated dose); glyburide 1.25 mg BID and 15 mg daily pioglitazone (pioglitazone was titrated monthly to a final dose of 45 mg daily).</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="29"/>
            <count group_id="B2" value="29"/>
            <count group_id="B3" value="58"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="58"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44.8" spread="9.7"/>
                    <measurement group_id="B2" value="45.0" spread="10.7"/>
                    <measurement group_id="B3" value="44.9" spread="10.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Beta-cell Function - C-peptide AUC (Area Under the Curve)</title>
        <description>C-peptide AUC during a 3-hours mixed meal challenge testing</description>
        <time_frame>72 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metformin &amp; Insulin</title>
            <description>Insulin NovoLog 70/30 BID adjusted to target fasting blood glucose level of 70 to 110 mg/dL and postprandial blood sugar &lt; 140 mg/dL and Metformin 2,000 mg/day (or maximum tolerated dose).</description>
          </group>
          <group group_id="O2">
            <title>Metformin, GLyburide &amp; Pioglitazone</title>
            <description>Metformin 2,000 mg (or maximum tolerated dose); glyburide 1.25 mg BID and 15 mg daily pioglitazone (pioglitazone was titrated monthly to a final dose of 45 mg daily).</description>
          </group>
        </group_list>
        <measure>
          <title>Beta-cell Function - C-peptide AUC (Area Under the Curve)</title>
          <description>C-peptide AUC during a 3-hours mixed meal challenge testing</description>
          <units>ng*min/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2096" spread="795"/>
                    <measurement group_id="O2" value="1725" spread="618"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Insulin Sensitivity as Measure be Matsuda Index</title>
        <description>C-peptide-based Matsuda index using following formula: Matsuda index = 500,00 / root square [(fasting c-peptide x fasting glucose x 333) x (average c-peptide 0-120 mins x average glucose 0-120 mins x 333). Higher the Matsuda index, better the insulin sensitivity.</description>
        <time_frame>72 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metfomin &amp; Insulin</title>
            <description>Insulin NovoLog 70/30 BID adjusted to target fasting blood glucose level of 70 to 110 mg/dL and postprandial blood sugar &lt; 140 mg/dL and Metformin 2,000 mg/day (or maximum tolerated dose).</description>
          </group>
          <group group_id="O2">
            <title>Metfomin, Pioglitazone &amp; Glyburide</title>
            <description>Metformin 2,000 mg (or maximum tolerated dose); glyburide 1.25 mg BID and 15 mg daily pioglitazone (pioglitazone was titrated monthly to a final dose of 45 mg daily).</description>
          </group>
        </group_list>
        <measure>
          <title>Insulin Sensitivity as Measure be Matsuda Index</title>
          <description>C-peptide-based Matsuda index using following formula: Matsuda index = 500,00 / root square [(fasting c-peptide x fasting glucose x 333) x (average c-peptide 0-120 mins x average glucose 0-120 mins x 333). Higher the Matsuda index, better the insulin sensitivity.</description>
          <units>index</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.12" spread="2.62"/>
                    <measurement group_id="O2" value="2.45" spread="1.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bet-cell Function Measured by Disposition Index</title>
        <description>Disposition index was measured by multiplying the insulin secretion (C-peptide AUC/C-peptide AUC glucose) by the Matsuda index. Disposition index reflects the beta-cell function adjusted for total body insulin sensitivity</description>
        <time_frame>72 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metfomin &amp; Insulin</title>
            <description>Insulin NovoLog 70/30 BID adjusted to target fasting blood glucose level of 70 to 110 mg/dL and postprandial blood sugar &lt; 140 mg/dL and Metformin 2,000 mg/day (or maximum tolerated dose).</description>
          </group>
          <group group_id="O2">
            <title>Metfomin, Pioglitazone &amp; Glyburide</title>
            <description>Metformin 2,000 mg (or maximum tolerated dose); glyburide 1.25 mg BID and 15 mg daily pioglitazone (pioglitazone was titrated monthly to a final dose of 45 mg daily).</description>
          </group>
        </group_list>
        <measure>
          <title>Bet-cell Function Measured by Disposition Index</title>
          <description>Disposition index was measured by multiplying the insulin secretion (C-peptide AUC/C-peptide AUC glucose) by the Matsuda index. Disposition index reflects the beta-cell function adjusted for total body insulin sensitivity</description>
          <units>index</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.12" spread="0.07"/>
                    <measurement group_id="O2" value="0.16" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Weight</title>
        <description>Body Weight</description>
        <time_frame>72 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metfomin and Insulin</title>
            <description>Insulin NovoLog 70/30 BID adjusted to target fasting blood glucose level of 70 to 110 mg/dL and postprandial blood sugar &lt; 140 mg/dL and Metformin 2,000 mg/day (or maximum tolerated dose).</description>
          </group>
          <group group_id="O2">
            <title>Metformin, Pioglitazone and Glyburide</title>
            <description>Metformin 2,000 mg (or maximum tolerated dose); glyburide 1.25 mg BID and 15 mg daily pioglitazone (pioglitazone was titrated monthly to a final dose of 45 mg daily).</description>
          </group>
        </group_list>
        <measure>
          <title>Weight</title>
          <description>Body Weight</description>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="107.7" spread="31.1"/>
                    <measurement group_id="O2" value="107.9" spread="31.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Inflammatory Markers - hsCRP</title>
        <description>Inflammatory markers - hsCRP (C reactive protein)</description>
        <time_frame>72 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metfomin &amp; Insulin</title>
            <description>Insulin NovoLog 70/30 BID adjusted to target fasting blood glucose level of 70 to 110 mg/dL and postprandial blood sugar &lt; 140 mg/dL and Metformin 2,000 mg/day (or maximum tolerated dose).</description>
          </group>
          <group group_id="O2">
            <title>Metfomin, Pioglitazone &amp; Glyburide</title>
            <description>Metformin 2,000 mg (or maximum tolerated dose); glyburide 1.25 mg BID and 15 mg daily pioglitazone (pioglitazone was titrated monthly to a final dose of 45 mg daily).</description>
          </group>
        </group_list>
        <measure>
          <title>Inflammatory Markers - hsCRP</title>
          <description>Inflammatory markers - hsCRP (C reactive protein)</description>
          <units>mg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.9" spread="7.7"/>
                    <measurement group_id="O2" value="6.1" spread="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Inflammatory Markers -Fibrinogen</title>
        <description>Inflammatory markers - Fibrinogen</description>
        <time_frame>72 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metfomin &amp; Insulin</title>
            <description>Insulin NovoLog 70/30 BID adjusted to target fasting blood glucose level of 70 to 110 mg/dL and postprandial blood sugar &lt; 140 mg/dL and Metformin 2,000 mg/day (or maximum tolerated dose).</description>
          </group>
          <group group_id="O2">
            <title>Metfomin, Pioglitazone &amp; Glyburide</title>
            <description>Metformin 2,000 mg (or maximum tolerated dose); glyburide 1.25 mg BID and 15 mg daily pioglitazone (pioglitazone was titrated monthly to a final dose of 45 mg daily).</description>
          </group>
        </group_list>
        <measure>
          <title>Inflammatory Markers -Fibrinogen</title>
          <description>Inflammatory markers - Fibrinogen</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="399.0" spread="82.6"/>
                    <measurement group_id="O2" value="395.4" spread="98.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Inflammatory Markers - PAI-1</title>
        <description>Inflammatory markers - PAI-1 (Plasminogen activator inhibitor type 1)</description>
        <time_frame>72 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metfomin &amp; Insulin</title>
            <description>Insulin NovoLog 70/30 BID adjusted to target fasting blood glucose level of 70 to 110 mg/dL and postprandial blood sugar &lt; 140 mg/dL and Metformin 2,000 mg/day (or maximum tolerated dose).</description>
          </group>
          <group group_id="O2">
            <title>Metfomin, Pioglitazone &amp; Glyburide</title>
            <description>Metformin 2,000 mg (or maximum tolerated dose); glyburide 1.25 mg BID and 15 mg daily pioglitazone (pioglitazone was titrated monthly to a final dose of 45 mg daily).</description>
          </group>
        </group_list>
        <measure>
          <title>Inflammatory Markers - PAI-1</title>
          <description>Inflammatory markers - PAI-1 (Plasminogen activator inhibitor type 1)</description>
          <units>IU/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.9" spread="11.7"/>
                    <measurement group_id="O2" value="16.7" spread="18.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life Survey (QoL) - Current Health Perception</title>
        <description>Current health perception was measured at randomization and 72 months later using the modified Diabetes Quality of Life Clinical Trial Questionnaire. This questionnaire addresses several areas with respect to diabetes QoL. Answers are in the form of a Likert scale score of 1–5, where 1 = much better than 3 months ago; 2 - Somewhat better now than 3 months ago; 3 - About the same; 4 - Somewhat worse now than 3 months ago; 5 Much worse now than 3 months ago.</description>
        <time_frame>72 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metfomin &amp; Insulin</title>
            <description>Insulin NovoLog 70/30 BID adjusted to target fasting blood glucose level of 70 to 110 mg/dL and postprandial blood sugar &lt; 140 mg/dL and Metformin 2,000 mg/day (or maximum tolerated dose).</description>
          </group>
          <group group_id="O2">
            <title>Metfomin, Pioglitazone &amp; Glyburide</title>
            <description>Metformin 2,000 mg (or maximum tolerated dose); glyburide 1.25 mg BID and 15 mg daily pioglitazone (pioglitazone was titrated monthly to a final dose of 45 mg daily).</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life Survey (QoL) - Current Health Perception</title>
          <description>Current health perception was measured at randomization and 72 months later using the modified Diabetes Quality of Life Clinical Trial Questionnaire. This questionnaire addresses several areas with respect to diabetes QoL. Answers are in the form of a Likert scale score of 1–5, where 1 = much better than 3 months ago; 2 - Somewhat better now than 3 months ago; 3 - About the same; 4 - Somewhat worse now than 3 months ago; 5 Much worse now than 3 months ago.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" spread="0.9"/>
                    <measurement group_id="O2" value="2.9" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life Survey (QoL) - Treatment Satisfaction</title>
        <description>Treatment satisfaction was measured at randomization and 72 months later using the modified Diabetes Quality of Life Clinical Trial Questionnaire. This questionnaire addresses several areas with respect to diabetes QoL. Answers are in the form of a Likert scale score of 1–5, where 1 - very satisfied; 2 - moderately satisfied; 3 - neither satisfied nor dissatisfied; 4 - moderately dissatisfied; 5 - very dissatisfied.</description>
        <time_frame>72 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metfomin &amp; Insulin</title>
            <description>Insulin NovoLog 70/30 BID adjusted to target fasting blood glucose level of 70 to 110 mg/dL and postprandial blood sugar &lt; 140 mg/dL and Metformin 2,000 mg/day (or maximum tolerated dose).</description>
          </group>
          <group group_id="O2">
            <title>Metfomin, Pioglitazone &amp; Glyburide</title>
            <description>Metformin 2,000 mg (or maximum tolerated dose); glyburide 1.25 mg BID and 15 mg daily pioglitazone (pioglitazone was titrated monthly to a final dose of 45 mg daily).</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life Survey (QoL) - Treatment Satisfaction</title>
          <description>Treatment satisfaction was measured at randomization and 72 months later using the modified Diabetes Quality of Life Clinical Trial Questionnaire. This questionnaire addresses several areas with respect to diabetes QoL. Answers are in the form of a Likert scale score of 1–5, where 1 - very satisfied; 2 - moderately satisfied; 3 - neither satisfied nor dissatisfied; 4 - moderately dissatisfied; 5 - very dissatisfied.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" spread="0.5"/>
                    <measurement group_id="O2" value="2.1" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life Survey (QoL) - Treatment Impact</title>
        <description>Treatment impact was measured at randomization and 72 months later using the modified Diabetes Quality of Life Clinical Trial Questionnaire. This questionnaire addresses several areas with respect to diabetes QoL. Answers are in the form of a Likert scale score of 1–5, where 1 - very satisfied; 2 - moderately satisfied; 3 - neither satisfied nor dissatisfied; 4 - moderately dissatisfied; 5 - very dissatisfied.</description>
        <time_frame>72 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metfomin &amp; Insulin</title>
            <description>Insulin NovoLog 70/30 BID adjusted to target fasting blood glucose level of 70 to 110 mg/dL and postprandial blood sugar &lt; 140 mg/dL and Metformin 2,000 mg/day (or maximum tolerated dose).</description>
          </group>
          <group group_id="O2">
            <title>Metfomin, Pioglitazone &amp; Glyburide</title>
            <description>Metformin 2,000 mg (or maximum tolerated dose); glyburide 1.25 mg BID and 15 mg daily pioglitazone (pioglitazone was titrated monthly to a final dose of 45 mg daily).</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life Survey (QoL) - Treatment Impact</title>
          <description>Treatment impact was measured at randomization and 72 months later using the modified Diabetes Quality of Life Clinical Trial Questionnaire. This questionnaire addresses several areas with respect to diabetes QoL. Answers are in the form of a Likert scale score of 1–5, where 1 - very satisfied; 2 - moderately satisfied; 3 - neither satisfied nor dissatisfied; 4 - moderately dissatisfied; 5 - very dissatisfied.</description>
          <units>score on a sale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" spread="0.2"/>
                    <measurement group_id="O2" value="1.8" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life Survey (QoL) - Social or Vocational Worry</title>
        <description>Social or vocational worry was measured at randomization and 72 months later using the modified Diabetes Quality of Life Clinical Trial Questionnaire. This questionnaire addresses several areas with respect to diabetes QoL. Answers are in the form of a Likert scale score of 0–5, where 0 - does not apply; 1 - never; 2 - seldom; 3 - sometimes; 4 - often; 5 - all of the time.</description>
        <time_frame>72 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metfomin &amp; Insulin</title>
            <description>Insulin NovoLog 70/30 BID adjusted to target fasting blood glucose level of 70 to 110 mg/dL and postprandial blood sugar &lt; 140 mg/dL and Metformin 2,000 mg/day (or maximum tolerated dose).</description>
          </group>
          <group group_id="O2">
            <title>Metfomin, Pioglitazone &amp; Glyburide</title>
            <description>Metformin 2,000 mg (or maximum tolerated dose); glyburide 1.25 mg BID and 15 mg daily pioglitazone (pioglitazone was titrated monthly to a final dose of 45 mg daily).</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life Survey (QoL) - Social or Vocational Worry</title>
          <description>Social or vocational worry was measured at randomization and 72 months later using the modified Diabetes Quality of Life Clinical Trial Questionnaire. This questionnaire addresses several areas with respect to diabetes QoL. Answers are in the form of a Likert scale score of 0–5, where 0 - does not apply; 1 - never; 2 - seldom; 3 - sometimes; 4 - often; 5 - all of the time.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" spread="0.3"/>
                    <measurement group_id="O2" value="1.7" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life Survey (QoL) - Hypoglycemia Fear</title>
        <description>Hypoglycemia fear was measured at randomization and 72 months later using the modified Diabetes Quality of Life Clinical Trial Questionnaire. This questionnaire addresses several areas with respect to diabetes QoL. Answers are in the form of a Likert scale score of 1–5, where 1 - never worry; 2 - rarely water; 3 - sometimes worry; 4 - often worry; 5 - very often worry</description>
        <time_frame>72 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metfomin &amp; Insulin</title>
            <description>Insulin NovoLog 70/30 BID adjusted to target fasting blood glucose level of 70 to 110 mg/dL and postprandial blood sugar &lt; 140 mg/dL and Metformin 2,000 mg/day (or maximum tolerated dose).</description>
          </group>
          <group group_id="O2">
            <title>Metfomin, Pioglitazone &amp; Glyburide</title>
            <description>Metformin 2,000 mg (or maximum tolerated dose); glyburide 1.25 mg BID and 15 mg daily pioglitazone (pioglitazone was titrated monthly to a final dose of 45 mg daily).</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life Survey (QoL) - Hypoglycemia Fear</title>
          <description>Hypoglycemia fear was measured at randomization and 72 months later using the modified Diabetes Quality of Life Clinical Trial Questionnaire. This questionnaire addresses several areas with respect to diabetes QoL. Answers are in the form of a Likert scale score of 1–5, where 1 - never worry; 2 - rarely water; 3 - sometimes worry; 4 - often worry; 5 - very often worry</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" spread="0.3"/>
                    <measurement group_id="O2" value="1.8" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life Survey (QoL) - Glycemia Control Perception</title>
        <description>Glycemia control perception was measured at randomization and 72 months later using the modified Diabetes Quality of Life Clinical Trial Questionnaire. This questionnaire addresses several areas with respect to diabetes QoL. Answers are in the form of a scale score of 1–7, where 1 - extremely controlled and 7 - not at all controlled.</description>
        <time_frame>72 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metfomin &amp; Insulin</title>
            <description>Insulin NovoLog 70/30 BID adjusted to target fasting blood glucose level of 70 to 110 mg/dL and postprandial blood sugar &lt; 140 mg/dL and Metformin 2,000 mg/day (or maximum tolerated dose).</description>
          </group>
          <group group_id="O2">
            <title>Metfomin, Pioglitazone &amp; Glyburide</title>
            <description>Metformin 2,000 mg (or maximum tolerated dose); glyburide 1.25 mg BID and 15 mg daily pioglitazone (pioglitazone was titrated monthly to a final dose of 45 mg daily).</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life Survey (QoL) - Glycemia Control Perception</title>
          <description>Glycemia control perception was measured at randomization and 72 months later using the modified Diabetes Quality of Life Clinical Trial Questionnaire. This questionnaire addresses several areas with respect to diabetes QoL. Answers are in the form of a scale score of 1–7, where 1 - extremely controlled and 7 - not at all controlled.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" spread="2.8"/>
                    <measurement group_id="O2" value="2.0" spread="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life Survey (QoL) - Lifestyle Flexibility</title>
        <description>Lifestyle flexibility was measured at randomization and 72 months later using the modified Diabetes Quality of Life Clinical Trial Questionnaire. This questionnaire addresses several areas with respect to diabetes QoL. Answers are in the form of a Likert scale score of 1 to 5, where 1 - a great deal of choice; 2 - a lot of choice; 3 - some choice; 4 - a little choice; 5 - no choice.</description>
        <time_frame>72 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metfomin &amp; Insulin</title>
            <description>Insulin NovoLog 70/30 BID adjusted to target fasting blood glucose level of 70 to 110 mg/dL and postprandial blood sugar &lt; 140 mg/dL and Metformin 2,000 mg/day (or maximum tolerated dose).</description>
          </group>
          <group group_id="O2">
            <title>Metfomin, Pioglitazone &amp; Glyburide</title>
            <description>Metformin 2,000 mg (or maximum tolerated dose); glyburide 1.25 mg BID and 15 mg daily pioglitazone (pioglitazone was titrated monthly to a final dose of 45 mg daily).</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life Survey (QoL) - Lifestyle Flexibility</title>
          <description>Lifestyle flexibility was measured at randomization and 72 months later using the modified Diabetes Quality of Life Clinical Trial Questionnaire. This questionnaire addresses several areas with respect to diabetes QoL. Answers are in the form of a Likert scale score of 1 to 5, where 1 - a great deal of choice; 2 - a lot of choice; 3 - some choice; 4 - a little choice; 5 - no choice.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" spread="0.6"/>
                    <measurement group_id="O2" value="2.0" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life Survey (QoL) - Social Stigma</title>
        <description>Social stigma was measured at randomization and 72 months later using the modified Diabetes Quality of Life Clinical Trial Questionnaire. This questionnaire addresses several areas with respect to diabetes QoL. Answers are in the form of a Likert scale score of 1 to 5, where 1- strongly agree; 2 - somewhat agree; 3 - neither agree nor disagree; 4 - somewhat disagree; 5 - strongly disagree.</description>
        <time_frame>72 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metfomin &amp; Insulin</title>
            <description>Insulin NovoLog 70/30 BID adjusted to target fasting blood glucose level of 70 to 110 mg/dL and postprandial blood sugar &lt; 140 mg/dL and Metformin 2,000 mg/day (or maximum tolerated dose).</description>
          </group>
          <group group_id="O2">
            <title>Metfomin, Pioglitazone &amp; Glyburide</title>
            <description>Metformin 2,000 mg (or maximum tolerated dose); glyburide 1.25 mg BID and 15 mg daily pioglitazone (pioglitazone was titrated monthly to a final dose of 45 mg daily).</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life Survey (QoL) - Social Stigma</title>
          <description>Social stigma was measured at randomization and 72 months later using the modified Diabetes Quality of Life Clinical Trial Questionnaire. This questionnaire addresses several areas with respect to diabetes QoL. Answers are in the form of a Likert scale score of 1 to 5, where 1- strongly agree; 2 - somewhat agree; 3 - neither agree nor disagree; 4 - somewhat disagree; 5 - strongly disagree.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" spread="1.2"/>
                    <measurement group_id="O2" value="2.2" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life Survey (QoL) - Satisfaction With Insulin Treatment</title>
        <description>Satisfaction with insulin treatment was measured at randomization and 72 months later using the modified Diabetes Quality of Life Clinical Trial Questionnaire. This questionnaire addresses several areas with respect to diabetes QoL. Answers are in the form of a scale score of 1 to 7, where 1 extremely satisfied to 7 - not at all satisfied.</description>
        <time_frame>72 months</time_frame>
        <population>Data were not collected from participants in the &quot;Metfomin, Pioglitazone &amp; Glyburide&quot; Arm/Group since patients did not receive insulin.</population>
        <group_list>
          <group group_id="O1">
            <title>Metfomin &amp; Insulin</title>
            <description>Insulin NovoLog 70/30 BID adjusted to target fasting blood glucose level of 70 to 110 mg/dL and postprandial blood sugar &lt; 140 mg/dL and Metformin 2,000 mg/day (or maximum tolerated dose).</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life Survey (QoL) - Satisfaction With Insulin Treatment</title>
          <description>Satisfaction with insulin treatment was measured at randomization and 72 months later using the modified Diabetes Quality of Life Clinical Trial Questionnaire. This questionnaire addresses several areas with respect to diabetes QoL. Answers are in the form of a scale score of 1 to 7, where 1 extremely satisfied to 7 - not at all satisfied.</description>
          <population>Data were not collected from participants in the &quot;Metfomin, Pioglitazone &amp; Glyburide&quot; Arm/Group since patients did not receive insulin.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life Survey (QoL) - Willingness to Continue Insulin Treatment</title>
        <description>Willingness to continue insulin treatment was measured at randomization and 72 months later using the modified Diabetes Quality of Life Clinical Trial Questionnaire. This questionnaire addresses several areas with respect to diabetes QoL. Answers are in the form of a scale score of 1 to 7, where 1 extremely willing to 7 - not at all willing.</description>
        <time_frame>72 months</time_frame>
        <population>Data were not collected from participants in the &quot;Metfomin, Pioglitazone &amp; Glyburide&quot; Arm/Group since patients did not receive insulin.</population>
        <group_list>
          <group group_id="O1">
            <title>Metfomin &amp; Insulin</title>
            <description>Insulin NovoLog 70/30 BID adjusted to target fasting blood glucose level of 70 to 110 mg/dL and postprandial blood sugar &lt; 140 mg/dL and Metformin 2,000 mg/day (or maximum tolerated dose).</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life Survey (QoL) - Willingness to Continue Insulin Treatment</title>
          <description>Willingness to continue insulin treatment was measured at randomization and 72 months later using the modified Diabetes Quality of Life Clinical Trial Questionnaire. This questionnaire addresses several areas with respect to diabetes QoL. Answers are in the form of a scale score of 1 to 7, where 1 extremely willing to 7 - not at all willing.</description>
          <population>Data were not collected from participants in the &quot;Metfomin, Pioglitazone &amp; Glyburide&quot; Arm/Group since patients did not receive insulin.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Metfomin &amp; Insulin</title>
          <description>Insulin NovoLog 70/30 BID adjusted to target fasting blood glucose level of 70 to 110 mg/dL and postprandial blood sugar &lt; 140 mg/dL and Metformin 2,000 mg/day (or maximum tolerated dose).</description>
        </group>
        <group group_id="E2">
          <title>Metfomin, Pioglitazone &amp; Glyburide</title>
          <description>Metformin 2,000 mg (or maximum tolerated dose); glyburide 1.25 mg BID and 15 mg daily pioglitazone (pioglitazone was titrated monthly to a final dose of 45 mg daily).</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <description>Cardiac arrest leading to sudden death.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>GI disturbance</sub_title>
                <description>Gastrointestinal adverse events included the following conditions: nausea, diarrhea, flatulence and or vomiting. These events were not reported separately.</description>
                <counts group_id="E1" events="15" subjects_affected="5" subjects_at_risk="29"/>
                <counts group_id="E2" events="18" subjects_affected="6" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Relatively small trial, but longest (6-year) follow-up.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Ildiko Lingvay</name_or_title>
      <organization>UT Southwestern Medical Center</organization>
      <phone>214-648-2779</phone>
      <email>ildiko.lingvay@utsouthwestern.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

